-
Investors Should Watch: Utah Medical Products Inc. (NASDAQ:UTMD), Sage Therapeutics (NASDAQ:SAGE), LNB Bancorp Inc. (NASDAQ:LNBB), Old Dominion Freight Line (NASDAQ:ODFL), LivePerson (NASDAQ:LPSN)
On January 29, Utah Medical Products, Inc. (NASDAQ:UTMD) said that company concluded another excellent financial year in 2014, exceeding its projections provided in its 2013 SEC Form 10-K. Despite significant recent foreign currency exchange (FX) rate headwinds, fourth quarter (4Q) sales and operating profits were up. In 4Q 2014 and year of 2014, UTMD’s changes…
-
Top Movers: Sage Therapeutics (NASDAQ:SAGE), Comcast Corporation (NASDAQ:CMCSA), Franklin Financial Corporation (NASDAQ:FRNK), Friedman Industries, Incorporated (NYSEMKT:FRD), Northern Oil and Gas (NYSEMKT:NOG)
SAGE Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-threatening, rare central nervous system (CNS) disorders on 17 December announced that the company has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). Sage Therapeutics, Inc. (NASDAQ:SAGE) in last trading activity increased 5.74% to close at $38.70. Company weekly performance is…
-
Top News: Sage Therapeutics (NASDAQ:SAGE), Tesla Motors Inc (NASDAQ:TSLA), Capstone Turbine Corp. (NASDAQ:CPST), VASCO Data Security International (NASDAQ:VDSI), Baidu Inc (NASDAQ:BIDU)
SAGE Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, November 11th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.10. During the same quarter in the prior year, the company posted ($2.98) earnings per share. On average, analysts predict that SAGE Therapeutics will…
-
Notable Ups And Down: Sage Therapeutics (NASDAQ:SAGE), Chevron Corporation (NYSE:CVX), Cognizant Technology Solutions Corporation (NASDAQ:CTSH), Allot Communications (NASDAQ:ALLT), Capstone Turbine (NASDAQ:CPST)
On Dec. 17, Sage Therapeutics, Inc. (NASDAQ:SAGE) announced that the company has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI). The addition to the NASDAQ Biotechnology Index will become effective upon market open on Dec. 22, 2014. Sage Therapeutics, Inc. (NASDAQ:SAGE) in last trading activity moved down -0.32% to close at $40.19. Company…
-
Top Stocks: Sage Therapeutics (NASDAQ:SAGE), SFX Entertainment Inc. (NASDAQ:SFXE), Maxim Integrated Products (NASDAQ:MXIM), The Scotts Miracle-Gro Company (NYSE:SMG), Microsoft (NASDAQ:MSFT)
On Dec 17, Sage Therapeutics, Inc. (NASDAQ:SAGE) announced that the company has been selected for addition to the NASDAQ Biotechnology Index The addition to the NASDAQ Biotechnology Index will become effective upon market open on Dec. 22, 2014. Sage Therapeutics, Inc. (NASDAQ:SAGE) in last trading activity moved down -0.32% to close at $40.19. Company weekly…
-
Biotech Bullish Movers: Arrowhead Research Corp. (NASDAQ:ARWR), Sunesis Pharmaceuticals (NASDAQ:SNSS), Sorrento Therapeutics (NASDAQ:SRNE), La Jolla Pharmaceutical (NASDAQ:LJPC), Sage Therapeutics (NASDAQ:SAGE)
Shares of Arrowhead Research Corp (NASDAQ:ARWR) were the target of a large drop in short interest in November. As of November 28th, there was short interest totalling 13,200,529 shares, a drop of 14.4% from the November 14th total of 15,419,897 shares, Stock Ratings Network reports. Arrowhead Research Corp. (NASDAQ:ARWR) in last trading activity moved up…
-
Biotech Losers to Watch: Halozyme Therapeutics (NASDAQ:HALO), iBio (NYSEMKT:IBIO), NewLink Genetics Corporation (NASDAQ:NLNK), Radius Health (NASDAQ:RDUS), Sage Therapeutics (NASDAQ:SAGE)
Halozyme Therapeutics Inc. (NASDAQ:HALO) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $14.6 million versus the consensus estimate of $16.5 million. Halozyme Therapeutics, Inc. (NASDAQ:HALO) in last trading activity moved down -5.36% to close at $8.82. Company weekly performance is -5.36% while its…
-
Hot Biotech Gainers: Illumina Inc. (NASDAQ:ILMN), NewLink Genetics Corporation (NASDAQ:NLNK), Oncothyreon Inc (NASDAQ:ONTY), Agios Pharmaceuticals(NASDAQ:AGIO), Sage Therapeutics(NASDAQ:SAGE)
Illumina, Inc. (NASDAQ:ILMN) announced its financial results for Q3 2014 on Monday and beat analyst expectations. The company reported revenue of $481 million, above the average estimates of $451.2 million and a 35 percent increase compared to $357 million in the third quarter of 2013. GAAP net income for the quarter was $93 million, or…